Ganitumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Description of Ganitumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade

Introduction

Ganitumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R) and is currently being developed as a potential therapeutic for various types of cancer. In this article, we will delve into the structure, activity, and potential applications of Ganitumab Biosimilar in the field of cancer research.

Structure of Ganitumab Biosimilar

Ganitumab Biosimilar is a recombinant monoclonal antibody that is produced using recombinant DNA technology. It is a humanized antibody, meaning that it is derived from non-human sources but has been modified to be more similar to human antibodies. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains contain four constant regions (Fc) and one variable region (Fab), while the light chains contain two constant regions and one variable region. The variable regions are responsible for the specificity of the antibody, as they bind to the target protein, IGF1R.

Activity of Ganitumab Biosimilar

The main target of Ganitumab Biosimilar is the IGF1R, a transmembrane receptor that is involved in cell growth, differentiation, and survival. IGF1R is overexpressed in various types of cancer, making it an attractive therapeutic target. Ganitumab Biosimilar binds to the extracellular domain of IGF1R and blocks the binding of insulin-like growth factors (IGFs), which are the natural ligands of IGF1R. This prevents the activation of downstream signaling pathways that promote cell growth and survival, ultimately inhibiting tumor growth.

In addition to blocking IGF1R, Ganitumab Biosimilar also has an antibody-dependent cell-mediated cytotoxicity (ADCC) activity. This means that the antibody can bind to immune cells, such as natural killer (NK) cells, and activate them to kill cancer cells that express IGF1R. This dual mechanism of action makes Ganitumab Biosimilar a promising therapeutic agent for cancer treatment.

Potential Applications of Ganitumab Biosimilar

Ganitumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including pancreatic, lung, and breast cancer. Preclinical studies have shown promising results in inhibiting tumor growth and enhancing the efficacy of other cancer treatments, such as chemotherapy and radiation therapy.

One potential application of Ganitumab Biosimilar is in combination therapy with other targeted therapies. For example, IGF1R is often co-expressed with other therapeutic targets, such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Combining Ganitumab Biosimilar with inhibitors of these targets may have a synergistic effect in inhibiting tumor growth and improving patient outcomes.

Another potential application of Ganitumab Biosimilar is in the treatment of drug-resistant cancers. IGF1R has been implicated in resistance to chemotherapy and targeted therapies, and Ganitumab Biosimilar may be able to overcome this resistance by targeting IGF1R.

Conclusion

In summary, Ganitumab Biosimilar is a promising monoclonal antibody that targets IGF1R and has the potential to be used as a therapeutic for various types of cancer. Its unique dual mechanism of action, targeting IGF1R and inducing ADCC, sets it apart from other targeted therapies and makes it a valuable addition to the arsenal of cancer treatments. Further clinical trials will determine the efficacy and safety of Ganitumab Biosimilar, and it may become an important tool in the fight against cancer.

SDS-PAGE for Ganitumab Biosimilar - Anti-IGF1R, CD221 mAb

Ganitumab Biosimilar - Anti-IGF1R, CD221 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.